Datavault AI (DVLT) Stock: $4B DelivMeds AI Platform Launched Through Wellgistics Partnership - Blockonomi

by · Blockonomi

Key Highlights

Table of Contents

Toggle

  • Datavault AI collaborates with Wellgistics on $4B DelivMeds AI healthcare solution.
  • Platform merges blockchain technology, artificial intelligence, and pharmacy networks.
  • QOLPOM™ technology powers wearable-based verification and drone medication delivery.
  • Tollo Health investment brings telemedicine, nutritional supplements, and AI wellness guidance.
  • Initial deployment begins in North Carolina before nationwide healthcare expansion.

Datavault AI (DVLT) closed at $0.4570, reflecting a 1.20% increase following an eventful trading session. The organization completed a definitive agreement with Wellgistics Health (NASDAQ:WGRX). This strategic alliance establishes DelivMeds AI, merging distributed ledger technology, machine learning, and pharmaceutical distribution.

Datavault AI Inc., DVLT

The strategic deal encompasses three simultaneous transactions with an aggregate valuation approaching $4 billion. Datavault AI broadens its PharmacyChain™ licensing framework to incorporate Healthcare-as-a-Service innovations. The company simultaneously obtains QOLPOM™ intellectual property rights and majority ownership in Tollo Health, LLC.

DelivMeds AI will incorporate EinsteinRx AI within blockchain-secured smart contract infrastructure. The solution enhances prescription oversight, patient interaction, and final-mile pharmaceutical distribution. National deployment commences in North Carolina during July 2026.

PharmacyChain License Enhancement

Datavault AI extended PharmacyChain™ capabilities to encompass Healthcare-as-a-Service innovations. The licensing agreement connects more than 6,500 pharmacies and 200 pharmaceutical producers across the country. EinsteinRx™ AI orchestrates eligibility confirmation, registration processes, and compliance monitoring at enterprise scale.

The infrastructure simultaneously processes prior authorization requests and direct-payment transactions effectively. Blockchain-based smart contracts guarantee secure, auditable prescription processing workflows. The ecosystem supports machine learning-powered logistics and tokenization of tangible healthcare assets.

The United States blockchain healthcare sector achieved $7.13 billion valuation in 2023. Analysts forecast growth to $595.31 billion by 2032, representing a 63.5% compound annual growth rate. DelivMeds AI establishes Datavault as a leader in this accelerating industry transformation.

QOLPOM Technology Portfolio Integration

Datavault AI secured QOLPOM™ intellectual property from EOS Technology and Scilex Holdings. This patent portfolio facilitates wearable-powered biometric authentication for individualized pharmaceutical distribution. The system incorporates Data Driven Drones™ for medical logistics and specimen retrieval.

The innovation addresses verification challenges and fraudulent activity in pharmaceutical supply chains. It simultaneously enhances final-mile access in remote and medically underserved regions. QOLPOM™ strengthens precision and security within telehealth and pharmaceutical operations.

Autonomous aerial delivery of healthcare supplies is anticipated to expand from $430 million in 2023 to $2.49 billion by 2032. DelivMeds AI capitalizes on this trajectory to broaden patient accessibility nationwide.

Tollo Health Investment Strategy

Tollo Health contributes clinical expertise to DelivMeds AI via virtual healthcare consultations and AI-powered wellness coaching. The organization provides therapeutic nutrition products addressing weight management, muscle deterioration, long COVID, and severe viral conditions. The NFL Alumni Health collaboration establishes direct patient connectivity.

This investment reinforces DelivMeds’ patient outreach capabilities and nationwide brand recognition. GLP-1 receptor agonist treatments, forecast to surge from $66 billion in 2025 to $185 billion in 2033, constitute a strategic market segment. The platform combines nutraceutical interventions with AI-enhanced mental health protocols.

The agreements remain contingent upon standard due diligence procedures, board authorizations, and finalization of binding contracts. DelivMeds AI unifies distributed ledger infrastructure, artificial intelligence capabilities, and national pharmaceutical reach. This initiative constitutes a $4 billion commitment to transforming patient-focused healthcare distribution.

 

✨ Limited Time Offer

Get 3 Free Stock Ebooks

Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.

  • Top 10 AI Stocks - Leading AI companies
  • Top 10 Crypto Stocks - Blockchain leaders
  • Top 10 Tech Stocks - Tech giants

📥 Get Your Free Ebooks

Advertise Here